Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study.

Publisher: Asian Association for the Study of Diabetes and Blackwell Pub. Asia Country of Publication: Japan NLM ID: 101520702 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2040-1124 (Electronic) Linking ISSN: 20401116 NLM ISO Abbreviation: J Diabetes Investig Subsets: MEDLINE

Original Publication: Tokyo : Asian Association for the Study of Diabetes and Blackwell Pub. Asia

Biomarkers/*analysis ; Cognition/*drug effects ; Diabetes Mellitus, Type 2/*drug therapy ; Hyperglycemia/*epidemiology ; Hypoglycemia/*epidemiology ; Hypoglycemic Agents/*adverse effects ; Hypoglycemic Agents/*classification; Adult ; Aged ; Blood Glucose/analysis ; Female ; Follow-Up Studies ; Glycated Hemoglobin/analysis ; Humans ; Hyperglycemia/chemically induced ; Hyperglycemia/pathology ; Hypoglycemia/chemically induced ; Hypoglycemia/pathology ; Hypoglycemic Agents/administration & dosage ; Japan/epidemiology ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Time Factors

Aims/introduction: Continuous glucose monitoring (CGM) metrics, such as times in range (TIR) and time below range, have been shown to be useful as clinical targets that complement glycated hemoglobin (HbA1c) for patients with type 2 diabetes mellitus. We investigated the relationships between TIR, glycemic variability and patient characteristics in patients with type 2 diabetes mellitus.
Materials and Methods: We carried out continuous glucose monitoring in 281 outpatients with type 2 diabetes mellitus who participated in a multicenter cohort (Hyogo Diabetes Hypoglycemia Cognition Complications) study.
Results: The results are shown as the median (interquartile range). The age, disease duration and HbA1c were 68 years (62-71 years), 13 years (7-23 years) and 6.9% (6.5-7.5%), respectively. TIR and standard deviation obtained by continuous glucose monitoring worsened significantly with increasing disease duration. Multiple regression analyses showed that disease duration (standard partial regression coefficient, β = -0.160, P = 0.003), diabetic peripheral neuropathy (β = -0.106, P = 0.033) and urinary albumin excretion (β = -0.100, P = 0.043) were useful explanatory factors for TIR. In contrast, HbA1c (β = -0.398, P < 0.001) and the use of antidiabetic drugs potentially associated with severe hypoglycemia (β = 0.180, P = 0.028), such as sulfonylureas, glinides and insulin, were useful explanatory factors for time below range in the elderly patients with type 2 diabetes mellitus.
Conclusions: The results of this study suggest that disease duration and diabetic complications are associated with TIR deterioration. In addition, low HbA1c levels and the use of antidiabetic drugs potentially associated with severe hypoglycemia might worsen the time below range in the elderly.
(© 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.)

Diabetol Int. 2018 Mar 27;9(1):1-45. (PMID: 30603347)
Diabetes Res Clin Pract. 2004 Dec;66 Suppl 1:S37-43. (PMID: 15563978)
J Diabetes Investig. 2021 Feb;12(2):244-253. (PMID: 32594655)
Expert Opin Drug Saf. 2010 Sep;9(5):675-81. (PMID: 20553106)
Diabetes Technol Ther. 2006 Dec;8(6):644-53. (PMID: 17109596)
Diabetes Care. 2020 Jan;43(Suppl 1):S66-S76. (PMID: 31862749)
Diabet Med. 2015 Feb;32(2):274-9. (PMID: 25307609)
Cardiovasc Diabetol. 2012 Oct 06;11:122. (PMID: 23039216)
J Diabetes Investig. 2017 Mar;8(2):243-249. (PMID: 27390272)
JAMA Intern Med. 2013 Jul 22;173(14):1300-6. (PMID: 23753199)
Diabetes Technol Ther. 2020 Oct;22(10):768-776. (PMID: 32167394)
J Diabetes Investig. 2017 Jan;8(1):126-128. (PMID: 28054465)
J Diabetes Investig. 2019 May;10(3):846-850. (PMID: 30307128)
Rev Endocr Metab Disord. 2016 Mar;17(1):103-10. (PMID: 26975588)
Diabetes Metab Res Rev. 2018 Nov;34(8):e3047. (PMID: 30028067)
Diabetes Res Clin Pract. 2015 May;108(2):342-9. (PMID: 25779865)
BMJ. 2013 Jul 29;347:f4533. (PMID: 23900314)
Diabetes Care. 2014;37(1):217-25. (PMID: 23939540)
Lancet. 1998 Sep 12;352(9131):837-53. (PMID: 9742976)
Diabetes. 2002 Jul;51(7):2170-8. (PMID: 12086947)
N Engl J Med. 2008 Jun 12;358(24):2545-59. (PMID: 18539917)
JAMA Intern Med. 2014 May;174(5):678-86. (PMID: 24615164)
Diabetol Metab Syndr. 2014 Dec 15;6(1):139. (PMID: 25530811)
Cardiovasc Diabetol. 2015 Jun 04;14:70. (PMID: 26041130)
N Engl J Med. 2003 Jun 5;348(23):2294-303. (PMID: 12788993)
Geriatr Gerontol Int. 2012 Apr;12 Suppl 1:18-28. (PMID: 22435937)
N Engl J Med. 2009 Jan 8;360(2):129-39. (PMID: 19092145)
Diabet Med. 2002 Oct;19(10):870-3. (PMID: 12358878)
Fam Pract. 2015 Feb;32(1):27-34. (PMID: 25194144)
Diabetes Care. 2018 Nov;41(11):2370-2376. (PMID: 30201847)
Diabetes Care. 2011 Jun;34(6):1329-36. (PMID: 21505211)
J Diabetes Investig. 2018 Mar 2;:. (PMID: 29498232)
Diabetes Care. 2009 Jan;32(1):187-92. (PMID: 19092168)
Diabetes Care. 1998 Nov;21(11):1870-5. (PMID: 9802735)
N Engl J Med. 2008 Jun 12;358(24):2560-72. (PMID: 18539916)
J Diabetes Res. 2020 Feb 06;2020:5817074. (PMID: 32090120)
Diabetes Care. 2019 Aug;42(8):1593-1603. (PMID: 31177185)
Diabetes Technol Ther. 2020 Feb;22(2):72-78. (PMID: 31524497)

faculty research grant (No.210790) Hyogo College of Medicine

Keywords: Continuous glucose monitoring; Hypoglycemia; Type 2 diabetes

0 (Biomarkers)
0 (Blood Glucose)
0 (Glycated Hemoglobin A)
0 (Hypoglycemic Agents)
0 (hemoglobin A1c protein, human)

Date Created: 20200629 Date Completed: 20211011 Latest Revision: 20240330

20240330

PMC7858127

10.1111/jdi.13336

32594655